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corrected for each patient. With the new 'corrected' errors 
and the other errors measured during follow-up CBCT, 
standard deviation was determined for each patient. 
Then they were added quadratically, ie each individual 
overall deviation were squared, added all squares and from 
the result the standard deviation of random errors (σ) was 
obtained. Finally, for each direction, the formulas of Van 
Herk & de Stroom were applied 
Results: The mean values of the systematic errors of the first 
5 CBCT were:Sver:0,3, Slong: 0,2 y Slat: 0,2. The standard 
deviation of the random errors was: σver: 1.43, σlong: 0.77 y 
σlat: 0.96. The results of applying the formulas of van Herk 





Conclusions: No statistically significant differences were 
found between the values obtained for each of the systems 
for calculating margin expansion. Therefore, we will evaluate 
which of the two will be applied in our patients, considering 
that Stroom formula obtains a margin assuring that 99% of 
CTV is within the 95% isodose and Van Herk formula obtains a 
margin which ensures that 90% of the population receives at 
least 95% of the prescribed dose to the CTV. 
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Purpose/Objective: The application of hypofractionated 
regimen allows to reduce the treatment time of radiotherapy 
(RT) and is theoretically associated with an improvement of 
the probability of cure in patients affected by prostatic 
carcinoma (CAP). However, hypofractionated RT could be 
associated with a higher incidence of late side effects. Many 
studies are currently in progress to assess the effectiveness 
of this irradiation modality, but definitive indications about 
tolerance and efficacy of this method are still missing. The 
aim of this study was the comparison of the therapeutic 
results recorded in two different studies of CAP RT, based on 
different dose fractionation. 
Materials and Methods: In this analysis were included 
patients enrolled in: 1) an observational study on RT of 
prostate +/- seminal vesicles with 3D technique and a dose of 
73.8 Gy (1.8 Gy/fraction); 2) a phase I-II study on RT of 
prostate +/- seminal vesicles with IGRT-IMRT-SIB technique 
and a dose of 65 Gy (2.6 Gy/fraction) +/- radiosurgical boost 
(5 Gy in single fraction). Biochemical recurrence-free survival 
(according to Phoenix-criteria), local control, disease-free 
and overall survival were evaluated using the Kaplan-Meier 
method. Survival curves were compared by logrank test 
(univariate analysis) or Cox Proportional Hazard Method 
(multivariate analysis, considering as covariates: risk class, 
RT-treatment modalities, lenght of hormonal therapy). 
Patients were classified according to NCCN 2014 risk 
categories. 
Results: 326 patients have been included in this comparison. 
The results of the analysis have been reported in the table. 
Also the multivariate analysis showed no difference in terms 
of biochemical and clinical outcomes between the two groups 
of patients (p: NS). 
 
Conclusions: Comparing two prospective studies, a 
hypofractionated treatment +/- stereotactic boost showed 
comparable results in terms of toxicity and biochemical 
outcome to the standard treatment. 
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Purpose/Objective: Postoperative radiotherapy improves 
prognosis in high risk prostate cancer patients. However, 5-
year biochemical recurrence free survival does not exceed 75 
- 80%. On the basis of several randomized trials, showing a 
